{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:51:39Z","timestamp":1794639099254,"version":"4.9.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adjuvant treatment with PD-1 inhibitors for 12 months has been the established standard of care for patients with resected stage IIB-IV cutaneous melanoma. In other solid tumours (e.g. breast and colorectal), a shorter duration of adjuvant chemotherapy has been shown to be non-inferior with improved toxicity profile. More recently, neoadjuvant immunotherapy with immune checkpoint inhibitors for clinically detectable stage III and stage IV disease has been introduced. There is no clear biological rationale for the chosen duration, and no studies have investigated duration of adjuvant treatment with immune checkpoint inhibitors. A reduced duration of adjuvant therapy could lead to less toxicity from reduced drug exposure, patients returning to normal life sooner, significantly lower drug costs and better healthcare resource utilization. There remains significant interest from patients and clinicians to address this important question.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Grand SLAM is a prospective phase III randomised, controlled international multi-centre non-inferiority study. The primary objective is to investigate if short (6 months) has equal efficacy as long (12 months) duration of (neo-)adjuvant immune checkpoint inhibition in relation to distant metastasis-free survival and relapse-free survival at landmark analysis at 2 years. After radical surgery of stage IIB-C, III or IV cutaneous melanoma, patients are randomly assigned 1:1 to short or long adjuvant treatment with either nivolumab or pembrolizumab. Patients who have received neoadjuvant treatment with major pathological response are excluded. The sample size of 1,880 patients was determined based on a non-inferiority margin of 4%, a significance level of 0.045 and 80% statistical power. An interim analysis will be conducted when 2\/3 of patients are accrued. Biomarkers and the role of food supplements for relapse (MelKo) will be investigated in prespecified substudies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This is the first randomised study to assess a shorter duration of adjuvant anti PD-1 antibody in cutaneous melanoma patients. As of March 2026, the study is recruiting patients in the Nordic countries. Centres in other countries will open shortly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT06488482. Date of registration: 2024-06-10.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15924-4","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:25:44Z","timestamp":1774621544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Patric","family":"Ejder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Jespersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Hernberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Elleg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalle","family":"Mattila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger Olofsson","family":"Bagge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Fountoukidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Brandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"O\u00b4Carrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Aranche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildur","family":"Helgadottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"Ullenhag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"15924_CR1","doi-asserted-by":"publisher","first-page":"1512942","DOI":"10.3389\/fonc.2024.1512942","volume":"14","author":"C Liu","year":"2024","unstructured":"Liu C, Liu X, Hu L, Li X, Xin H, Zhu S. Global, regional, and national burden of cutaneous malignant melanoma from 1990 to 2021 and prediction to 2045. Front Oncol. 2024;14:1512942.","journal-title":"Front Oncol"},{"issue":"5","key":"15924_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","volume":"22","author":"AMM Eggermont","year":"2021","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):643\u201354.","journal-title":"Lancet Oncol"},{"issue":"11","key":"15924_CR3","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandala M, Gogas H, Arance AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465\u201377.","journal-title":"Lancet Oncol"},{"issue":"11","key":"15924_CR4","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","volume":"29","author":"JM Kirkwood","year":"2023","unstructured":"Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, et al. Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023;29(11):2835\u201343.","journal-title":"Nat Med"},{"issue":"3","key":"15924_CR5","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.2217\/fon-2019-0666","volume":"16","author":"JJ Luke","year":"2020","unstructured":"Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, et al. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020;16(3):4429\u201338.","journal-title":"Future Oncol"},{"issue":"25","key":"15924_CR6","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1200\/JCO-24-02776","volume":"43","author":"GC Lodde","year":"2025","unstructured":"Lodde GC, Hassel JC, von Wasielewski I, Meier F, Mohr P, Kahler K, et al. Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma. J Clin Oncol. 2025;43(25):2793\u2013805.","journal-title":"J Clin Oncol"},{"issue":"18","key":"15924_CR7","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med. 2024;391(18):1696\u2013708.","journal-title":"N Engl J Med"},{"issue":"9","key":"15924_CR8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, Wright GP Jr., Yost KJ, Hyngstrom JR, et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023;388(9):813\u201323.","journal-title":"N Engl J Med"},{"key":"15924_CR9","unstructured":"(NIH) NIoH. A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery 2023 [updated 2025-03-07. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05608291"},{"key":"15924_CR10","unstructured":"(NIH) NIoH. A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma 2023 [updated 2024-11-18. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05933577"},{"issue":"10427","key":"15924_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632\u201344.","journal-title":"Lancet"},{"issue":"1","key":"15924_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S1470-2045(24)00627-2","volume":"26","author":"A Hauschild","year":"2025","unstructured":"Hauschild A, Garbe C, Ascierto PA, Demidov L, Dreno B, Dummer R, et al. Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey. Lancet Oncol. 2025;26(1):12\u20134.","journal-title":"Lancet Oncol"},{"issue":"64","key":"15924_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta23640","volume":"23","author":"T Iveson","year":"2019","unstructured":"Iveson T, Boyd KA, Kerr RS, Robles-Zurita J, Saunders MP, Briggs AH, et al. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technol Assess. 2019;23(64):1\u201388.","journal-title":"Health Technol Assess"},{"issue":"40","key":"15924_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta24400","volume":"24","author":"H Earl","year":"2020","unstructured":"Earl H, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, et al. Six versus 12 months\u2019 adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technol Assess. 2020;24(40):1\u2013190.","journal-title":"Health Technol Assess"},{"issue":"3","key":"15924_CR15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","volume":"4","author":"A Ribas","year":"2016","unstructured":"Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, et al. PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res. 2016;4(3):194\u2013203.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"15924_CR16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s43018-021-00180-1","volume":"2","author":"J Han","year":"2021","unstructured":"Han J, Zhao Y, Shirai K, Molodtsov A, Kolling FW, Fisher JL, et al. Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy. Nat Cancer. 2021;2(3):300\u201311.","journal-title":"Nat Cancer"},{"key":"15924_CR17","unstructured":"Markets RA. April. Checkpoint Inhibitors Market Report 2025 [updated 2025. Available from: https:\/\/www.researchandmarkets.com\/report\/checkpoint-inhibitors?srsltid=AfmBOoqktvjBa5Nleqpl37Lvs7qp23km5XYbeT8Gte9xAq9s-UD1uK5_."},{"issue":"5","key":"15924_CR18","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/10543406.2013.813522","volume":"23","author":"K Togo","year":"2013","unstructured":"Togo K, Iwasaki M. Optimal timing for interim analyses in clinical trials. J Biopharm Stat. 2013;23(5):1067\u201380.","journal-title":"J Biopharm Stat"},{"key":"15924_CR19","doi-asserted-by":"crossref","unstructured":"Naeser Y, Helgadottir H, Hansson J, Ingvar C, Elander NO, Flygare P, et al. Quality of life in the first year of follow-up in a randomized multicenter trial assessing the role of imaging after radical surgery of stage IIB-C and III cutaneous melanoma (TRIM Study). Cancers (Basel). 2022;14(4):1040.","DOI":"10.3390\/cancers14041040"},{"issue":"9","key":"15924_CR20","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/jnci\/djad081","volume":"115","author":"H Helgadottir","year":"2023","unstructured":"Helgadottir H, Ny L, Ullenhag GJ, Falkenius J, Mikiver R, Olofsson Bagge R, et al. Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study. J Natl Cancer Inst. 2023;115(9):1077\u201384.","journal-title":"J Natl Cancer Inst"},{"key":"15924_CR21","doi-asserted-by":"crossref","unstructured":"Weitemeyer MB-M, Helvind NM, Khan S, Bidstrup PE, Steffensen KD, Luczak AA, et al. A-434 - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage IIIA-D melanoma patients. EJC Skin Cancer. 2025;3(Suppl 1):A\u2013434.","DOI":"10.1016\/j.ejcskn.2025.100553"},{"issue":"14","key":"15924_CR22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017;377(14):1345\u201356.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15924-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15924-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15924-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:00:18Z","timestamp":1781643618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15924-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15924"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15924-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"After application to CTIS (EU CT no: 2023-509994-22-00), the study was approved 2024-10-10 for centres in Sweden and Norway, and 2024-10-15 for Finnish centres. Each patient included in the study has signed and dated informed consent in accordance with the EU-directive on clinical trials, the Helsinki declaration, ICH-GCP and applicable national regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"460"}}